Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Prevent-HF
NCT06677060Phase 3Recruiting
- Sponsor
- AstraZeneca
- Start
- Mar 2025
- Primary completion
- Dec 2029
- Modality
- Small Molecules
- Countries
- 35
01
Overview
Phase 3, randomised, double-blind trial in heart failure (HF) comparing Baxdrostat/Dapagliflozin with Placebo/Dapagliflozin (2 arms). Primary endpoint: Risk of an HF event or CV death at 38 months. Started Mar 2025; status: recruiting.
02
Drugs
baxdrostat
03
Conditions
heart failure (HF)
Beyond the preview
Go deeper on NCT06677060.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06677060.